4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (NNK)

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, commonly known as NNK, is a potent tobacco-specific nitrosamine and a major carcinogen found in tobacco products and cigarette smoke. It is a pro-carcinogen that requires metabolic activation, primarily by cytochrome P450 enzymes such as CYP1A2 and CYP2A6, to form reactive intermediates that create DNA adducts, leading to mutations in critical genes like KRAS. In addition to its mutagenic properties, NNK acts as a high-affinity agonist for beta-adrenergic receptors and alpha-7 nicotinic acetylcholine receptors, which triggers signaling pathways that promote cell proliferation, survival, and epithelial-mesenchymal transition. These dual actions make NNK a significant driver of various tobacco-related malignancies, including lung, pancreatic, and esophageal cancers. Research into NNK focuses on understanding its metabolic pathways, its role in tumor initiation and progression, and the development of chemopreventive agents that can inhibit its activation or block its receptor-mediated effects.

Other names

NNK4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone4-(Methylnitrosamino)-1-(3-pyridinyl)-1-butanoneTobacco-specific nitrosamine4,1,1-butanone

Drugs targeting the effects of this molecule primarily work by inhibiting its metabolic activation by cytochrome P450 enzymes (e.g., PEITC inhibiting CYP1A2) or by antagonizing the cell surface receptors it activates, such as beta-adrenergic and nicotinic acetylcholine receptors, thereby blocking pro-survival and proliferative signaling.